IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Speciality Medicines
IPO is a SME Upcoming IPO coming on
BSE SME with an
IPO
size of
[●]
.
This IPO falls under the
Pharmaceutical sector, which has seen
39 IPOs
to date. Key sector metrics such as average PE ratio, IPO size, EBITDA margin, and
PAT margin are compared below with the figures from the
Speciality Medicines
IPO.
You can do performance analysis for Speciality Medicines IPO with Listed IPOs in the Pharmaceutical sector and review their IPO performance based on Merchant banker, Listing price, IPO Valuation and other metrics.
This IPO report captures the post-listing performance of IPOs in the Pharmaceutical sector, featuring key metrics like offer price, listing gain, and CMP to help investors assess return potential and sector sentiment.
| NAME | OFFER PRICE | LISTING PRICE | LISTING GAIN | CMP | CMP % |
|---|---|---|---|---|---|
|
Astonea Labs
IPO
Financial Report >> |
₹ 135.00 | ₹ 137.45 | 1.81% | ₹ 149.00 | 10% |
|
Accretion Pharmaceuticals
IPO
Financial Report >> |
₹ 101.00 | ₹ 79.00 | -21.78% | ₹ 70.20 | -30% |
|
Hamps Bio
IPO
Financial Report >> |
₹ 51.00 | ₹ 101.74 | 99.49% | ₹ 39.00 | -24% |
|
Onyx Biotec
IPO
Financial Report >> |
₹ 61.00 | ₹ 56.75 | -6.97% | ₹ 51.00 | -16% |
|
Medicamen Organics
IPO
Financial Report >> |
₹ 34.00 | ₹ 144.70 | 325.59% | ₹ 43.30 | 27% |
|
Quest Laboratories
IPO
Financial Report >> |
₹ 97.00 | ₹ 147.35 | 51.91% | ₹ 95.60 | -1% |
|
Zenith Drugs
IPO
Financial Report >> |
₹ 79.00 | ₹ 105.15 | 33.10% | ₹ 71.40 | -10% |
|
Sunrest Lifescience
IPO
Financial Report >> |
₹ 84.00 | ₹ 79.80 | -5.00% | ₹ 50.45 | -40% |
|
Mono Pharmacare
IPO
Financial Report >> |
₹ 28.00 | ₹ 30.45 | 8.75% | ₹ 25.65 | -8% |
|
Shelter Pharma
IPO
Financial Report >> |
₹ 42.00 | ₹ 41.96 | -0.10% | ₹ 45.05 | 7% |
|
Vilin Bio
IPO
Financial Report >> |
₹ 30.00 | ₹ 30.00 | [●] | ₹ 26.95 | -10% |
|
Remus Pharmaceuticals
IPO
Financial Report >> |
₹ 1229.00 | ₹ 1711.00 | 39.22% | ₹ 1891.35 | 54% |
|
Infinium Pharmachem
IPO
Financial Report >> |
₹ 135.00 | ₹ 141.50 | 4.81% | ₹ 297.00 | 120% |
|
Sotac Pharmaceuticals
IPO
Financial Report >> |
₹ 111.00 | ₹ 115.00 | 3.60% | ₹ 150.00 | 35% |
|
Sudarshan Pharma
IPO
Financial Report >> |
₹ 73.00 | ₹ 73.00 | [●] | ₹ 29.22 | -60% |
|
Patron Exim
IPO
Financial Report >> |
₹ 27.00 | ₹ 28.40 | 5.19% | ₹ 6.05 | -78% |
|
Trident Lifeline
IPO
Financial Report >> |
₹ 101.00 | ₹ 108.15 | 7.08% | ₹ 287.00 | 184% |
|
JFL Life
IPO
Financial Report >> |
₹ 61.00 | ₹ 66.50 | 9.02% | ₹ 16.50 | -73% |
|
Dipna Pharmachem
IPO
Financial Report >> |
₹ 38.00 | ₹ 33.40 | -12.11% | ₹ 22.61 | -41% |
|
Jeena Sikho
IPO
Financial Report >> |
₹ 150.00 | ₹ 173.50 | 15.67% | ₹ 471.05 | 214% |
|
Achyut Healthcare
IPO
Financial Report >> |
₹ 20.00 | ₹ 21.15 | 5.75% | ₹ 3.48 | -83% |
|
Evoq Remedies
IPO
Financial Report >> |
₹ 27.00 | ₹ 23.75 | -12.04% | ₹ 5.34 | -80% |
|
Fabino Life
IPO
Financial Report >> |
₹ 36.00 | ₹ 40.35 | 12.08% | ₹ 30.80 | -14% |
|
Chandra Bhagat
IPO
Financial Report >> |
₹ 51.00 | ₹ 51.76 | 1.49% | ₹ 58.00 | 14% |
|
Earum Pharmaceuticals
IPO
Financial Report >> |
₹ 36.00 | ₹ 36.05 | 0.14% | ₹ 1.02 | -97% |
|
Cian Healthcare
IPO
Financial Report >> |
₹ 61.00 | ₹ 61.50 | 0.82% | ₹ 4.27 | -93% |
|
Par Drugs
IPO
Financial Report >> |
₹ 51.00 | ₹ 51.45 | 0.88% | ₹ 95.54 | 87% |
|
Deccan Health
IPO
Financial Report >> |
₹ 100.00 | ₹ 113.40 | 13.40% | ₹ 20.50 | -80% |
|
Medico Remedies
IPO
Financial Report >> |
₹ 100.00 | ₹ 97.15 | -2.85% | ₹ 41.78 | 109% |
|
Beta Drugs
IPO
Financial Report >> |
[●] | ₹ 101.95 | 19.94% | ₹ 1734.30 | 1940% |
|
Vanta Bioscience
IPO
Financial Report >> |
[●] | ₹ 50.20 | 0.40% | ₹ 27.32 | -45% |
|
Dhruv Wellness
IPO
Financial Report >> |
[●] | ₹ 19.50 | -2.50% | ₹ 5.32 | -73% |
|
ANG Lifesciences
IPO
Financial Report >> |
[●] | ₹ 96.00 | 20.00% | ₹ 28.00 | -65% |
|
Vaishali Pharma
IPO
Financial Report >> |
[●] | ₹ 70.35 | -2.29% | ₹ 11.60 | -19% |
|
Zota Health
IPO
Financial Report >> |
[●] | ₹ 125.60 | 0.48% | ₹ 974.50 | 680% |
|
Sakar Healthcare
IPO
Financial Report >> |
[●] | ₹ 52.15 | 4.30% | ₹ 351.65 | 603% |
|
Kwality Pharmaceuticals
IPO
Financial Report >> |
[●] | ₹ 44.50 | -1.11% | ₹ 1060.40 | 2256% |
|
Bajaj Healthcare
IPO
Financial Report >> |
[●] | ₹ 171.50 | 0.88% | ₹ 504.85 | 2870% |
|
Ganga Pharmaceuticals
IPO
Financial Report >> |
[●] | ₹ 14.50 | -3.33% | ₹ 14.80 | -1% |
Speciality Medicines IPO Draft red herring prospectus (DRHP) and Red Herring prospectus (RHP) are available below.
The peers of
Speciality Medicines ,
include other listed companies operating in the
(Pharmaceutical) segment. These peer companies typically
offer similar services Some of the notable peers as per the DRHP of this company
are
.
See the complete list of
current IPO
Peer Comparison is the method of evaluating an entity by comparing its performance, size of business form other entities operating in same industry or sector. It involves financial analysis bycomparing key financial metrics like Profitability, Net worth, Market Capitalization and Leverage. Peer comparison is beneficial for investors to make informed investment decisions and to identify any potential risks. IPO Performance tracker
Peer comparison helps to identify companies in the same sector with a similar business. It helps to compare the financial performance and valuation against its listed peers. An investor or an analyst can decide whether the IPO price is justified when compared to its peers. An investor can make informed decision whether to apply to IPO or not on basis of peer comparison. Know the process of DRHP and Peer companies Information required to be disclosed in DRHP.
As of now 39 SME IPOs are listed in this sector indicating strong growth in this sector. Choosing the best IPO depends on factors like, financial performance, valuation, market trends and future growth plans. IPO Review and performance.
A good PE Ratio for Pharmaceutical sector depends on various factors like, performance of the company, market conditions, company valuation and IPO Size. PE Ratio varies from sector to sector and company to company. Know the average PE Multiple in each sector.
Currently 39 companies are listed under Pharmaceutical sector. Based on the latest data from the Stock Exchanges. Choose the Best Merchant Banker from the Merchant Banker List
Performance of companies depends on various factors like, profits, future plans, Market share, PE Ratio etc. By assessing these factors investor can make better investment decisions.Speciality Medicines Peer comparison provides IPO analysis of companies listed in this sector, on the basis of different Key performance indicators (KPI)like, Listing Gain of peers, current market price, PE Ratio and IPO Size.
Upcoming IPO refers to companies which have filed their DRHP with the Stock exchange and are awaiting approval from NSE Emerge or BSE SME. 13 companies have filed their DRHP for SME IPO under Pharmaceutical sector. .New IPO 2025-2026 and Upcoming IPO
PE Multiple is a metrics that is widely used for IPO Valuation. Merchant bankers in coordination with the company decides the PE Multiple.The PE Multiple depends on various factors and it should be analyzed in coordination with other financial metrics. Know the PE ratio of your company with PE Calculator provided by IPOplatform
Speciality Medicines operates in Pharmaceutical and . The Issue is listed on BSE SME in Jul, 2025. Speciality Medicines IPO size was with Issue price of .
Merchant Banker(s) of Speciality Medicines IPO: Ekadrisht Capital Private Limited
Speciality Medicines IPO subscription was X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Speciality Medicines IPO listed at a listing price of against the offer price of .
The current market price of Speciality Medicines is .
Why Us?
